Clinical Trial ProgressThe interim data for the trial demonstrated a remarkable >60% complete response rate, indicating significant potential for a non-invasive alternative to Mohs surgery.
Market OpportunityThere is a significant market opportunity for a non-surgical method to treat basal cell carcinoma, impacting around 3 million patients annually in the US, with a revenue potential of over $2 billion.
Product DevelopmentMedicus Pharma Ltd is advancing SkinJect, a novel dissolvable microneedle patch for non-invasive therapeutic delivery, offering a safer, non-surgical method for treating basal cell carcinoma.